Michael Matson, an analyst from Needham, reiterated the Buy rating on Atricure. The associated price target remains the same with $45.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Michael Matson has given his Buy rating due to a combination of factors related to Atricure’s competitive position and growth resilience. He notes that although Edwards Lifesciences plans to introduce a rival to AtriClip, Atricure has already weathered Medtronic’s Penditure launch, which only temporarily slowed U.S. Appendage Management growth before it rebounded to high‑teens levels.
He also highlights that Edwards lacks complementary ablation and pain management tools and has limited exposure to CABG procedures, which represent the majority of open‑heart surgeries, potentially weakening its competitive stance in surgical LAAC. Given AtriClip’s entrenched market position and these competitive dynamics, Matson expects Atricure to maintain at least low‑teens revenue growth even after the Edwards launch, supporting his continued Buy recommendation.
In another report released yesterday, Piper Sandler also maintained a Buy rating on the stock with a $50.00 price target.